Impact of body mass index on survival outcome in patients with differentiated thyroid cancer

Publication date: Available online 28 February 2017
Source:Brazilian Journal of Otorhinolaryngology
Author(s): Yousif AL-Ammar, Bader AL-Mansour, Omar AL-Rashood, Mutahir A. Tunio, Tahera Islam, Mushabbab AL-Asiri, Khalid Hussain AL-Qahtani
IntroductionIncreased body mass index (BMI) is known to be associated with the high prevalence of Differentiated Thyroid Cancers (DTC); however data on its impact on survival outcome after thyroidectomy and adjuvant therapy is scanty.ObjectiveWe aimed to evaluate the impact of BMI on overall survival (OS) and disease free survival (DFS) rates in patients with DTC.MethodsBetween 2000 and 2011, 209 patients with DTC (papillary, follicular, hurthle cell) were treated with thyroidectomy followed by adjuvant radioactive iodine-131 (RAI) therapy and thyroid-stimulating hormone (TSH) suppression. Based on BMI, patients were divided into five groups; (a) <18.5kg/m² (underweight); (b) 18.5–25kg/m² (normal weight); (c) 26–30kg/m² (overweight); (d) 31–40kg/m² (obese) and (e) >40kg/m² (morbid obese). Various demographic, clinical and treatment characteristics and related toxicity and outcomes (OS, and DFS) were analyzed and compared.ResultsMedian follow up period was 5.2years (0.6–10). Mean BMI was 31.3kg/m² (17–72); BMI 31–40kg/m² was predominant (89 patients, 42.6%) followed by 26–30kg/m² seen in 58 patients (27.8%). A total of 18 locoregional recurrences (8.6%) and 12 distant metastasis (5.7%) were seen. The 10 year DFS and OS rates were 83.1% and 58.0% respectively. No significant impact of BMI on OS or DFS rates was found (p=0.081). Similarly, multivariate analysis showed that BMI was not an independent prognostic factor for OS and DFS.ConclusionAlthough BMI can increase the risk of thyroid cancer, it has no impact on treatment outcome; however, further trials are warranted.



http://ift.tt/2lkC9tu